Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Purpose: Metastatic melanoma is characterized by extremely poor survival rates and hence novel therapies are urgently required. The ability of many anticancer drugs to activate autophagy, a lysosomal-mediated catabolic process which usually promotes cell survival, suggests targeting the autophagy pathway may be a novel means to augment therapy. Experimental Design: Autophagy and apoptosis were assessed in vitro in human melanoma cell lines in response to clinically achievable concentrations of the endoplasmic reticulum (ER) stress-inducing drugs fenretinide or bortezomib, and in vivo using a s.c. xenograft model. Results: Autophagy was activated in response to fenretinide or bortezomib in B-RAF wild-type cells, shown by increased conversion of LC3 to the autophagic vesicle-associated form (LC3-II) and redistribution to autophagosomes and autolysosomes, increased acidic vesicular organelle formation and autophagic vacuolization. In contrast, autophagy was significantly reduced in B-RAF–mutated melanoma cells, an effect attributed partly to oncogenic B-RAF. Rapamycin treatment was unable to stimulate LC3-II accumulation or redistribution in the presence of mutated B-RAF, indicative of de-regulated mTORC1-dependent autophagy. Knockdown of Beclin-1 or ATG7 sensitized B-RAF wild-type cells to fenretinide- or bortezomib-induced cell death, demonstrating a pro-survival function of autophagy. In addition, autophagy was partially reactivated in B-RAF–mutated cells treated with the BH3 mimetic ABT737 in combination with fenretinide or bortezomib, suggesting autophagy resistance is partly mediated by abrogated Beclin-1 function. Conclusions: Our findings suggest inhibition of autophagy in combination with ER stress-inducing agents may represent a means by which to harness autophagy for the therapeutic benefit of B-RAF wild-type melanoma. Clin Cancer Res; 17(8); 2216–26. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One study reports that BRAFV600E overexpression in melanoma cells decreases basal autophagy levels relative to BRAF wild-type cells through a Beclin1-dependent mechanism96.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., & Yoshimori, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5720 · Cited by 6,605
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1100356 · Cited by 5,894
Self-citationGuidelines for the use and interpretation of assays for monitoring autophagy
Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J. A., et al. (2012) · Autophagy · doi:10.4161/auto.19496 · Cited by 4,330
Kimura, S., Noda, T., & Yoshimori, T. (2007) · Autophagy · doi:10.4161/auto.4451 · Cited by 2,278
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
Klionsky, D. J., Abeliovich, H., Agostinis, P., Agrawal, D. K., Aliev, G., Askew, D. S., Baba, M., Baehrecke, E. H., Bahr, B. A., Ballabio, A., et al. (2008) · Autophagy · doi:10.4161/auto.5338 · Cited by 2,230
Self-citationAutophagy: molecular machinery for self-eating
Yorimitsu, T., & Klionsky, D. J. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401765 · Cited by 1,535
ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence
Cagnol, S., & Chambard, J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07366.x · Cited by 1,290
A Role for Ubiquitin in Selective Autophagy
Kirkin, V., McEwan, D. G., Novak, I., & Dikic, I. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.026 · Cited by 1,239
Life and death partners: apoptosis, autophagy and the cross-talk between them
Eisenberg-Lerner, A., Bialik, S., Simon, H.-U., & Kimchi, A. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.33 · Cited by 1,183
Cited by
Mechanisms and prevention of UV‐induced melanoma
Sample, A., & He, Y. (2018) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/phpp.12329 · Cited by 372
Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis
Gagliardi, M., Cotella, D., Santoro, C., Corà, D., Barlev, N. A., Piacentini, M., & Corazzari, M. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2143-7 · Cited by 165
Self-citationZHAO, G., HAN, X., ZHENG, S., LI, Z., SHA, Y., NI, J., SUN, Z., QIAO, S., & SONG, Z. (2016) · Oncology Reports · doi:10.3892/or.2015.4413 · Cited by 163
Corazzari, M., Rapino, F., Ciccosanti, F., Giglio, P., Antonioli, M., Conti, B., Fimia, G. M., Lovat, P. E., & Piacentini, M. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.183 · Cited by 162
“Autophagy is primarily a pro-survival process that is upregulated in advanced stages of melanoma,(3) particularly in those tumours harbouring hyperactivating mutations in BRAF, to sustain cell survival and counteract apoptotic signalling induced by chemotherapeutic agents.(3,20,30) The contribution of chronic ER stres…”
BackgroundResultInfluentialSelf-citationExploiting Cannabinoid-Induced Cytotoxic Autophagy to Drive Melanoma Cell Death
Armstrong, J. L., Hill, D. S., McKee, C. S., Hernandez-Tiedra, S., Lorente, M., Lopez-Valero, I., Eleni Anagnostou, M., Babatunde, F., Corazzari, M., Redfern, C. P. F., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.45 · Cited by 161
“Alongside genetic changes, adaption to ER stress and the aberrant control of autophagy have emerged as key drivers of malignancy and therapy resistance in advanced melanoma (Armstrong et al., 2011; Corazzari et al., 2013).”
BackgroundMethodSelf-citation
Metadata
- Authors
- Armstrong, J. L., Corazzari, M., Martin, S., Pagliarini, V., Falasca, L., Hill, D. S., Ellis, N., Al Sabah, S., Redfern, C. P. F., Fimia, G. M., Piacentini, M., & Lovat, P. E.
- Affiliations
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- Authors' Affiliations: 1Dermatological Sciences, Institute of Cellular Medicine, Medical School, and 2Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, UK; 3National Institute for Infectious Disease, ‘L. Spallanzani’, and 4University of Tor Vergata, Rome, Italy
- Corresponding author
- Lovat, Penny E.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2011-04-14
- Volume
- 17
- Issue
- 8
- Pages
- 2216-2226
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2122402825
- Cited by
- 65
- References
- 49
- Citations by year
- 2026: 1 · 2023: 2 · 2022: 1 · 2021: 7 · 2020: 4 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 6 · 2015: 7 · 2014: 8 · 2013: 12 · 2012: 3
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- AIRUS (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Abbott Laboratories
- JGW Patterson Foundation
- British Skin Foundation
- Newcastle University
- European Commission
- Fondazione Telethon
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Calcium signaling and nucleotide metabolism
- Keywords
- melanoma, BRAF mutation, autophagy, autophagy inhibition, endoplasmic reticulum stress, fenretinide, bortezomib, LC3-II, Beclin-1, ATG7, ABT-737, BH3 mimetics, mTORC1, apoptosis, rapamycin, combination therapy
- MeSH terms
- Bortezomib, Animals, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Biphenyl Compounds, Boronic Acids, Endoplasmic Reticulum, Female, Humans, Luminescent Proteins, Melanoma, Microscopy, Fluorescence, Microtubule-Associated Proteins, Nitrophenols, Piperazines, Pyrazines, Sulfonamides, Blotting, Western, Signal Transduction, Apoptosis, Fenretinide, Xenograft Model Antitumor Assays, RNA Interference, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-3003
- The paper
- Armstrong, J. L., Corazzari, M., Martin, S., Pagliarini, V., Falasca, L., Hill, D. S., Ellis, N., Al Sabah, S., Redfern, C. P. F., Fimia, G. M., Piacentini, M., & Lovat, P. E. (2011). Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-3003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.